For years, investors in large pharmaceutical companies treated the pricing environment as a domestic problem. What the government charges Medicare, what Medicaid rebates cost, what the Inflation Reduction Act negotiated away. The contract documents released over the weekend change that framing entirely.
The revenue-sharing provision is part of Pfizer’s most-favored-nation drug-pricing agreement with the U.S. government, applying to medicines already on the market. It is effective from January 1, 2026, through January 20, 2029. Pfizer agreed to share a portion of its net increased revenue from charging higher prices abroad with HHS. Consumer watchdog Public Citizen released the contract Saturday after obtaining it through a Freedom of Information Act lawsuit.
The blunt reality for dividend investors is this: the upside from higher overseas prices, which was supposed to compensate for domestic concessions, now has a claimant. Washington gets a cut before shareholders do. The exact percentage of revenue Pfizer must share, the medicines covered, and other terms were redacted from the documents. That opacity is itself a risk, because investors cannot model the drag.
The White House was direct about the intent. White House spokesperson Kush Desai said foreign prices are going to increase and that the foreign-revenue provisions are intended to ensure incremental revenue from higher prices abroad benefit American patients, not drugmakers. That is a policy statement that tells you whose side of the ledger the administration cares about.
The Tariff Deadline Adds Pressure
This matters more sharply right now because the Section 232 pharmaceutical tariffs take effect on July 31, 2026, for companies listed in Annex III and on September 29, 2026, for all others. For covered products, those tariffs can reach as high as 100%. The MFN arrangement was, in part, the price Pfizer paid to avoid that wall. Under the April 2, 2026 Section 232 proclamation, companies that have entered into MFN pharmaceutical pricing agreements with HHS can qualify for a zero tariff rate until January 20, 2029.
That tradeoff looks rational until you examine what was surrendered. Companies outside Annex III generally face higher tariff exposure starting September 29, 2026, but the proclamation also outlines pathways to reduced rates for qualifying onshoring plans, and a zero rate for companies with MFN pricing agreements. So the zero tariff is the reward for the revenue-sharing obligation. The question for Merck, AstraZeneca, Johnson & Johnson, and Eli Lilly is whether they struck similar terms, and on what basis investors should value the income streams those companies generate.
What Dividend Investors Should Watch
Pfizer is the clearest case to examine. Pfizer’s dividend has held at $0.43 per quarter through 2026, including the payment declared for the third quarter of 2026. Pfizer reaffirmed 2026 adjusted diluted EPS of $2.80 to $3.00 against a run-rate $1.72 annual payout. Coverage is adequate, but the revenue-sharing obligation makes any growth in overseas pricing power a shared asset rather than a shareholder asset.
Merck lifted its quarterly dividend to $0.85 for 2026, for a forward annualized rate of $3.40. Johnson & Johnson’s diversified portfolio across pharmaceuticals and medtech means tariff exposure was already lower than pure-play pharma peers, and the stock yields around 2% lately, with more than 60 consecutive years of dividend increases. Both companies face the same structural question: how much of any benefit from pushing foreign markets toward higher prices flows back to the company rather than to Washington?
Documents related to an Eli Lilly agreement were also released, while the administration has said that Pfizer, Lilly and two dozen other pharmaceutical manufacturers have struck agreements that are not fully public. That gap is where risk lives for investors trying to compare income reliability across the sector.
The Longer Wealth Thesis
Pharmaceutical dividends have long attracted income investors for the combination of pricing power and patent protection. The MFN framework does not eliminate either, but it adds a third party to the revenue equation. Investors in PFE, MRK, LLY, JNJ, and AZN should treat the redacted revenue-sharing rates as an unquantified liability until those terms are disclosed, and weight position sizes accordingly. A week before the Sept. 29 tariff date closes the window for companies without deals, the sector’s regulatory overhang is measurable and real. Diversifying across names that have already secured their zero-rate exemptions is preferable to concentrating in those still negotiating.
The enduring lesson here is that a dividend yield is not a fixed promise, it is the residual after every other claimant has been paid. Governments are now explicitly in that queue.
